Wealth Enhancement Advisory Services LLC Grows Stock Holdings in Celcuity Inc. (NASDAQ:CELC)

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Celcuity Inc. (NASDAQ:CELC) by 19.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,377 shares of the company’s stock after purchasing an additional 4,341 shares during the period. Wealth Enhancement Advisory Services LLC owned about 0.07% of Celcuity worth $345,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. lifted its position in Celcuity by 106.0% during the fourth quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company’s stock valued at $33,577,000 after purchasing an additional 1,319,700 shares during the period. Shay Capital LLC bought a new position in Celcuity during the fourth quarter valued at approximately $187,000. Nuveen Asset Management LLC lifted its position in Celcuity by 10.8% during the fourth quarter. Nuveen Asset Management LLC now owns 69,587 shares of the company’s stock valued at $911,000 after purchasing an additional 6,785 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Celcuity by 16.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company’s stock valued at $258,000 after purchasing an additional 2,756 shares during the period. Finally, J. Goldman & Co LP bought a new position in Celcuity during the fourth quarter valued at approximately $567,000. Institutional investors own 63.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $29.00 price objective on shares of Celcuity in a research report on Thursday, May 15th. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research report on Monday, May 19th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $30.80.

Celcuity Stock Down 3.6%

Shares of CELC stock opened at $12.11 on Friday. Celcuity Inc. has a 12 month low of $7.58 and a 12 month high of $19.77. The stock has a market cap of $458.56 million, a P/E ratio of -4.64 and a beta of 0.37. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The company has a 50 day simple moving average of $10.76 and a two-hundred day simple moving average of $11.29.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.09. On average, research analysts expect that Celcuity Inc. will post -2.62 earnings per share for the current year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.